All News
Filter News
Found 277 articles
-
Memory Treatment Centers is One of First to Administer Aduhelm Alzheimer's Infusion
8/9/2021
Memory Treatment Centers, a PURE Healthcare company (PURE), is excited to announce the completion of their first Aduhelm infusion. Memory Treatment Centers are among the first organizations to administer the new FDA approved Alzheimer's drug, Aduhelm.
-
A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.
-
Eisai said that they have initiated communication with the FDA to achieve "the most optimal regulatory pathway" for lecanemab.
-
KalGene Pharmaceuticals Inc. an Alzheimer's focused company using a next generation engineered drug candidate, has appointed new leadership
8/5/2021
KalGene Pharmaceuticals Inc. announced that Anthony J. Giovinazzo, MBA, C. Dir. & A.C.C. has joined the Board of Directors of the company as an Executive Chairman.
-
With the acquisition of the Roche stake, SoftBank has become one of the company’s biggest stakeholders.
-
ProMIS Neurosciences Issues Chairman’s MemorandumNotes and comments after the first AAIC meeting in the era of approved disease-modifying therapies for Alzheimer’s Disease
8/4/2021
ProMIS Neurosciences, Inc. issued today a Chairman’s memorandum, commenting on highlights of the recent 2021 Alzheimer’s Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.
-
Shares of Ardelyx, Inc. have fallen nearly 13% in premarket trading after the U.S. FDA rejected the company's chronic kidney disease drug, tenapanor.
-
Eli Lilly and Company presented data analysis from the Phase II TRAILBLAZER-ALZ study at the Alzheimer’s Association International Conference (AAIC) that supports the argument that decreases in beta-amyloid in Alzheimer’s disease slows cognitive decline.
-
Highlights From The Alzheimer's Association International Conference 2021
7/29/2021
Research presented at the Alzheimer's Association International Conference® 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.
-
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
7/29/2021
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo) today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer’s disease called ICARE AD-US, at the Alzheimer’s Association International Conference (AAIC), being held both virtually and in Denver, Colo. from July 26 – 30, 2021
-
Biogen reportedly withdrew a paper it had submitted to the medical journal JAMA after the publication requested edits before publication. It’s standard for a technical journal to request edits, but it is the nature of the edits—and in this case, the nature of the study— that raises questions.
-
One of the eagerly anticipated presentations at the AAIC being held this week is Biogen and its partner Eisai on their controversial drug ADUHELM™ (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.
-
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
7/26/2021
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer’s disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer’s Association International Conference (AAIC),
-
The company also issued an open letter to the Alzheimer’s disease community from Alfred Sandrock, which attempts to push back against negative media attention.
-
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
7/23/2021
Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021.
-
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
-
The antibody is still being evaluated in clinical studies, with a large-scale Phase III trial expected to wrap in the second half of 2022.
-
Eisai Alzheimer's Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer's Association International Conference (AAIC)
7/22/2021
Eisai Inc. announced today the presentation of findings from the company's robust Alzheimer's disease (AD) pipeline, including lecanemab (BAN2401).
-
Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.
-
Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow.